The Acquired (Autoimmune) Hemolytic Anemia drugs in development market research report provides comprehensive information on the therapeutics under development for Acquired (Autoimmune) Hemolytic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acquired (Autoimmune) Hemolytic Anemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acquired (Autoimmune) Hemolytic Anemia and features dormant and discontinued products.
GlobalData tracks 29 drugs in development for Acquired (Autoimmune) Hemolytic Anemia by 24 companies/universities/institutes. The top development phase for Acquired (Autoimmune) Hemolytic Anemia is preclinical with 12 drugs in that stage. The Acquired (Autoimmune) Hemolytic Anemia pipeline has 28 drugs in development by companies and one by universities/ institutes. Some of the companies in the Acquired (Autoimmune) Hemolytic Anemia pipeline products market are: Cellics Therapeutics, Nanjing IASO Biotherapeutics and Sanofi.
The key targets in the Acquired (Autoimmune) Hemolytic Anemia pipeline products market include B Lymphocyte Antigen CD19, Complement C1s Subcomponent, and IgG Receptor FcRn Large Subunit p51.
The key mechanisms of action in the Acquired (Autoimmune) Hemolytic Anemia pipeline product include Complement C1s Subcomponent Inhibitor with four drugs in Phase III. The Acquired (Autoimmune) Hemolytic Anemia pipeline products include six routes of administration with the top ROA being Intravenous and six key molecule types in the Acquired (Autoimmune) Hemolytic Anemia pipeline products market including Monoclonal Antibody, and Small Molecule.
Acquired (Autoimmune) Hemolytic Anemia overview
Acquired autoimmune hemolytic anemia (AIHA) is a rare blood disorder characterized by the immune system mistakenly attacking and destroying red blood cells. Red blood cells carry oxygen throughout the body, and their destruction leads to anemia (low red blood cell count), causing fatigue, pale skin, and other symptoms. AIHA can be classified into “warm” and “cold” types, depending on the temperature at which the antibodies bind to red blood cells. Warm AIHA is more common and occurs at body temperature, while cold AIHA happens at lower temperatures. Treatment may involve corticosteroids, immunosuppressive drugs, blood transfusions, and, in severe cases, splenectomy. Management aims to control the immune response and alleviate anemia-related symptoms.
For a complete picture of Acquired (Autoimmune) Hemolytic Anemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
